drugset
drugset / Trial / NCT04114461

Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers

NCT04114461 ↗

Phase 1 Completed 33 enrolled Hanlim Pharm. Co., Ltd.
RandomizedCrossoverOpen-labelBasic science

Summary

To evaluate the safety and pharmacokinetics of HL-TOF tab. 5 mg compared with those of XelJanz tab. in healthy volunteers

Timeline

Start
2019-11-06
Primary completion
2019-12-04
Completion
2019-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 5 mg Oral

Indications

No indication recorded.